Acquisition - November 5, 2019
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm. Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia. AstraZeneca will continue […]
Funding - October 23, 2019
AstraZeneca commits $35 million to non-communicable diseases
The company will extend funding for its award-winning Young Health Programme for a further five years with a pledge of $35 million to help to educate young people on the steps they can take to reduce the risk of non-communicable diseases. These diseases, which include cancer, diabetes, heart disease and heart failure, are responsible for […]
Pharma Business - October 21, 2019
AstraZeneca’s Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
The US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The approval is based on results from the DECLARE-TIMI 58 CV outcomes trial (CVOT), the largest sodium-glucose […]
Pharma Business - October 8, 2019
AstraZeneca’s Fasenra approved in the US for self-administration in a new pre-filled auto-injector
The US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen). The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial. The safety and tolerability of Fasenra in these trials were consistent with the established profile of the […]
Acquisition - October 1, 2019
AstraZeneca divests rights for Losec to Cheplapharm
AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm. The divestment includes medicines containing omeprazole marketed by AstraZeneca or its collaborators under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum medicine names. “This agreement forms part of our strategy of reducing the portfolio of mature medicines to enable […]
Collaboration - September 25, 2019
Nanoform and AstraZeneca initiate technology evaluation
Nanoform has announced the initiation of a technology evaluation of Nanoform’s CESS Technology across a range of AstraZeneca’s pharmaceutical products. The initiation of this study is to assess the added value that Nanoform’s technology could deliver across the pharmaceutical value chain. “We have always believed that our technology has significant value to offer the Pharma […]
